tbuckley/cabot-search huggingface dataset:
A Novel Chemosensitivity Profiling Platform for Small Acute Lymphoblastic Leukemia Cell Populations
Authors: Line Groth-Pedersen, Yen-Hsi Chen, Marianne Faber, Birgitte Klug Albertsen, Peder Skov Wehner, Steen Rosthoej, Thomas Leth Frandsen, Hanne Vibeke Marquart, Kjeld Schmiegelow
Journal: Blood (2014)
Differential Diagnosis of Polyuria
Journal: New England Journal of Medicine (1982)

Diabetes insipidus (DI) is a syndrome characterized by chronic polyuria and polydipsia. It can result from any of three basic defe cts: (a) inadequate urinary concentration caused by a deficiency in the secretion or action of the antidiuretic hormone vasopressin (neurogenic or nephrogenic DI), or excessive intake of water caused by a defect in (b) thirst or (c) psychological function (dipsogenic or psychogenic DI). These four types of DI can be differentiated clinically only if they present in a complete and classical form. However, more sophisticated diagnostic approaches involving assays of plasma vasopressin or closely monitored trials of antidiuretic therapy usually are necessary when the patient has mild or incomplete defects in thirst or vasopressin function. Accurate diagnostic differ­ entiation among the four basic types of DI is essential not only for safe and effective management but also for a proper understanding of the basic
Spike sorting for large, dense electrode arrays
Authors: Cyrille Rossant, Shabnam N Kadir, Dan F M Goodman, John Schulman, Maximilian L D Hunter, Aman B Saleem, Andres Grosmark, Mariano Belluscio, George H Denfield, Alexander S Ecker, Andreas S Tolias, Samuel Solomon, György Buzsáki, Matteo Carandini, Kenneth D Harris
Journal: Nature Neuroscience (2016)
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.
Authors: Z M Sthoeger, M Wakai, D B Tse, V P Vinciguerra, S L Allen, D R Budman, S M Lichtman, P Schulman, L R Weiselberg, N Chiorazzi
Journal: The Journal of Experimental Medicine (1989)

CD5-expressing B lymphocytes from patients with selected chronic lymphoproliferative disorders were used to determine whether monoclonal populations of CD5+ human B cells produce autoantibodies. CD5+ B cells from 19 patients with chronic lymphocytic leukemia (CLL) and one with diffuse well-differentiated lymphocytic lymphoma (DWDL) were cultured, with and without mitogenic stimulation, to obtain Ig from these cells. 17 of the 20 samples produced Ig in vitro. mAb from nine of the 17 patients were reactive with either IgG, ssDNA, or dsDNA. In every instance, the autoantibodies displayed monotypic L chain usage that correlated precisely with the L chain expressed on the CD5+ leukemic B cell surface. These monoclonal autoantibodies varied in their degree of antigenic specificity; some were quite specific, reacting with only one antigen, whereas others were polyspecific, reacting with two or all three autoantigens tested. Three features distinguish these autoantibodies from those observed in prior studies of CD5+ B cells. First, they are clearly the products of monoclonal populations of CD5+ cells; second, several react with dsDNA, a specificity not previously reported and often seen in association with significant autoimmune disorders; and third, two of the monoclonal autoantibodies secreted by the CD5+ clones were of the IgG class. Although not all of the Ig-producing, CD5-expressing clones elaborated mAbs reactive with the autoantigens tested, greater than 50% did. It is possible that with a broader autoantigenic panel or with larger quantities of CLL/DWDL-derived Ig, even more autoantibody-producing clones might be identified. These studies may have important implications for the antigenic specificity of subsets of human B lymphocytes as well as for lymphoproliferative and autoimmune disorders in general.
Public Health Consequences of a Flood Disaster— Iowa, 1993
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Successful Transthoracic Repair of a Ruptured Spleen
Authors: M Davies, N W Law, C D Johnson
Journal: Journal of the Royal Society of Medicine (1988)

This paper presents a case of trauma, in which both spleen and diaphragm were damaged. Thoracotomy was done to both preserve the spleen and repair the diaphragm. A short discussion on the advantages of splenic preservation and the importance of diagnosing and repairing a ruptured diaphragm follows.
Fitness in Young Adults as an Independent Predictor of Risk for Cardiovascular Disease
Authors: David E. Chiriboga, Ira S. Ockene
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
4th Congress of the European College of Sports &amp; Exercise Physicians (ECOSEP) scores goals! Opportunities for specialists, trainees, and students in many countries
Authors: Nikos Malliaropoulos, Heinz Lohrer, Amir Pakravan, Nat Padhiar
Journal: British Journal of Sports Medicine (2015)

The European College of Sports and Exercise Physicians (ECOSEP) is a specialty society of physician members within the European community. Our clear mission is to: (1) advance the competence of sports physicians via continuing medical education and research, (2) collaborate with other sports medicine organizations, and (3) provide reputable information to the public.

As one of BJSM 's 23 member societies we shaped this final issue of 2015. In our editorial on the challenges of managing exercise induced leg pain ( see page 1546 ), we draw attention to the fairly basic unanswered questions. There remains debate about its nomenclature, diagnosis, natural history and treatment options. Other that just that, it's well understood! Therefore, we call for an international consensus meeting.

One area where an international consensus meeting has made a major difference …
Retraction: An Effective Vaccine Strategy Protective against Antigenically Distinct Tumor Variants
Authors: Kevin D Pavelko, Michael J Hansen, Larry R Pease, Karin L Heckman
Journal: Cancer Research (2010)

Effective Vaccine Strategy Protective against Antigenically Distinct Tumor Variants," which was published in the April 1, 2008 issue of Cancer Research (1).In the course of investigating suspicious patterns of experimental results in the laboratory, a systematic and in-depth study of key findings in this article was carried out using blind protocols.In these repeat studies, no evidence was found to support our original conclusions that B7-DCXAb modulates dendritic cell functions.We do not believe our failure to reproduce our earlier findings is the result of a technical problem.A member of the B7-DCXAb investigative team, Dr. Suresh Radhakrishnan, who was involved in or had access to all work on this subject, was found in a formal institutional investigation to have engaged in scientific misconduct in unpublished experiments by manipulating another investigator's experiment involving the B7-DCXAb reagent.This finding of misconduct together with our inability to reproduce key findings using blinded protocols has undermined our confidence in our published reports.
A cluster of meningococcal disease caused by rifampicin-resistant C meningococci in France, April 2012
Authors: I Mounchetrou Njoya, A E Deghmane, M  K Taha, H Isnard, I Parent du Châtelet
Journal: Eurosurveillance (2012)

In April 2012, a cluster of two cases of meningococcal disease caused by rifampicin-resistant C meningococci was reported in the Champagne-Ardenne region, France. The two cases occurred in a student population living in the same town but studying at different schools. Bacteriological and epidemiological investigations of cases have shown that the isolates of both cases were non-differentiable.
Nicotine transdermal patch for smoking cessation using combination of hydrophilic and hydrophobic polymers as matrix film formers
Authors: Danaipat Sukphong, Thesisanin Rojanaratha, Marut Srivarnitpoom, Chaisan Sriwichupong, Garnpimol C. Ritthidej
Journal: Asian Journal of Pharmaceutical Sciences (2015)
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
Authors: Thomas Rauen, Frank Eitner, Christina Fitzner, Claudia Sommerer, Martin Zeier, Britta Otte, Ulf Panzer, Harm Peters, Urs Benck, Peter R. Mertens, Uwe Kuhlmann, Oliver Witzke, Oliver Gross, Volker Vielhauer, Johannes F.E. Mann, Ralf-Dieter Hilgers, Jürgen Floege
Journal: New England Journal of Medicine (2015)

The outcomes of immunosuppressive therapy, when added to supportive care, in patients with IgA nephropathy are uncertain.We conducted a multicenter, open-label, randomized, controlled trial with a two-group, parallel, group-sequential design. During a 6-month run-in phase, supportive care (in particular, blockade of the renin-angiotensin system) was adjusted on the basis of proteinuria. Patients who had persistent proteinuria with urinary protein excretion of at least 0.75 g per day were randomly assigned to receive supportive care alone (supportive-care group) or supportive care plus immunosuppressive therapy (immunosuppression group) for 3 years. The primary end points in hierarchical order were full clinical remission at the end of the trial (protein-to-creatinine ratio <0.2 [with both protein and creatinine measured in grams] and a decrease in the estimated glomerular filtration rate [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from baseline) and a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) at the end of the trial. The primary end points were analyzed with the use of logistic-regression models.The run-in phase was completed by 309 of 337 patients. The proteinuria level decreased to less than 0.75 g of urinary protein excretion per day in 94 patients. Of the remaining 162 patients who consented to undergo randomization, 80 were assigned to the supportive-care group, and 82 to the immunosuppression group. After 3 years, 4 patients (5%) in the supportive-care group, as compared with 14 (17%) in the immunosuppression group, had a full clinical remission (P=0.01). A total of 22 patients (28%) in the supportive-care group and 21 (26%) in the immunosuppression group had a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) (P=0.75). There was no significant difference in the annual decline in eGFR between the two groups. More patients in the immunosuppression group than in the supportive-care group had severe infections, impaired glucose tolerance, and weight gain of more than 5 kg in the first year of treatment. One patient in the immunosuppression group died of sepsis.The addition of immunosuppressive therapy to intensive supportive care in patients with high-risk IgA nephropathy did not significantly improve the outcome, and during the 3-year study phase, more adverse effects were observed among the patients who received immunosuppressive therapy, with no change in the rate of decrease in the eGFR. (Funded by the German Federal Ministry of Education and Research; STOP-IgAN ClinicalTrials.gov number, NCT00554502.).
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
Authors: Thomas Powles, Dorothee Nickles, Eliezer Van Allen, Colombe Chappey, Wei Zou, Marcin Kowanetz, Edward Kadel, Mitchell Denker, Zachary Boyd, Nicholas Vogelzang, Joseph Kim, Joaquim Bellmunt, Yohann Loriot, Charles G Drake, Carol O'Hear, Marcella Fasso, Priti Hegde, Sanjeev Mariathasan
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Atezolizumab (anti-PD-L1) has demonstrated robust clinical activity in UBC [[1][1]]. Elevated PD-L1 expression on tumor-infiltrating immune cells (IC) is associated with increased clinical efficacy; however, the contribution of other immune biomarkers is unknown. In this study, we
Nouvelle épidémie de trichinellose en région Midi-Pyrénées, France - Septembre-octobre 1998
Authors: C Hemery, S Haeghebaert
Journal: Eurosurveillance (1999)

Le 6 octobre 1998 onze cas de trichinellose survenus, en France, dans les departements de la Haute Garonne et du Tarn ont ete declares aux autorites sanitaires de la region Midi-Pyrenees (1). Les toutes premieres informations fournies par les medecins suggeraient que la viande de cheval pouvait etre le vehicule de l’infection, tous les cas ayant consomme de la viande de cheval achetee dans deux boucheries, l’une a Toulouse et l’autre a Castres. Une enquete epidemiologique, veterinaire et parasitologique a ete menee afin d’evaluer l’importance de cette epidemie et d’identifier le vehicule et la source de l’infection.
Soft Tissue Sarcoma, Version 2.2012
Authors: Margaret von Mehren, Robert S Benjamin, Marilyn M Bui, Ephraim S Casper, Ernest U Conrad, Thomas F DeLaney, Kristen N Ganjoo, Suzanne George, Ricardo Gonzalez, Martin J Heslin, John M Kane, Joel Mayerson, Sean V McGarry, Christian Meyer, Richard J O'Donnell, Benjamin Paz, John D Pfeifer, Raphael E Pollock, R Lor Randall, Richard F Riedel, Scott Schuetze, Karen D Schupak, Herbert S Schwartz, Sridhar Shankar, Brian A Van Tine, Jeffrey Wayne, Hema Sundar, Nicole R McMillian
Journal: Journal of the National Comprehensive Cancer Network (2012)

The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.
New Strategies in Stereotactic Radiotherapy for Oligometastases
Authors: David A. Palma, Alexander V. Louie, George B. Rodrigues
Journal: Clinical Cancer Research (2015)

Abstract Patients with metastatic solid tumors are usually treated with palliative intent. Systemic therapy and palliative radiation are often used, with the goals of prolonging survival or maintaining quality of life, but not of cure. In contrast to this paradigm, the theory of oligometastasis suggests that some patients who have a small number of metastases may be amenable to cure if all lesions can be eradicated. Aggressive treatment of patients with oligometastases, using either surgery or radiotherapy, has become more common in the past decade, yet in most situations, no randomized evidence is available to support such an approach. Stereotactic ablative radiotherapy (SABR) is a novel treatment for oligometastases, delivering large doses of radiotherapy in only a few treatments, with excellent rates of local control, and appears to be an excellent noninvasive alternative to surgical resection of metastases. This article reviews recent biologic and clinical data that support the existence of the oligometastatic state and discusses gaps in this evidence base. The emerging role for SABR in the management of this challenging patient population is discussed with a focus on ongoing clinical trials in an attempt to improve overall survival, delay progression, or induce immunologic anticancer effects through the abscopal effect. Clin Cancer Res; 21(23); 5198–204. ©2015 AACR.
Kinetics of chromatin activation and active DNA demethylation in vertebrate cells: Histone acetylation sets the stage for demethylase interactions with DNA resulting in demethylation
Authors: Ana Catalina D'Alessio, Moshe Szyf
Journal: Cancer Research (2004)

4168   Department of Pharmacology and Therapeutics, McGill University, Montreal Canada. The epigenome programs gene expression profiles of vertebrate cells. Disruption of epigenomic programming is widespread in cancer. The epigenome consists of the chromatin and its modifications such as histone acetylation and histone methylation and a pattern of DNA methylation at the CpG dinucleotide sequence. It was shown that methylated DNA directs the formation of inactive chromatin by recruiting methylated DNA binding proteins, which in turn target histone deacetylase and histone methyltransferase containing complexes to the methylated gene. An alternative hypothesis is that the DNA methylation pattern is a dynamic equilibrium of methylation and demethylation reactions and that the direction of the reaction is determined by chromatin structure. We have previously developed a transient transfection replication-independent active demethylation assay in living HEK 293 cells and showed that either pharmacological induction of histone acetylation by the HDAC inhibitor trichostatin A or a strong promoter triggers active demethylation of the in vitro methylated reporter GFP gene. To test the hypothesis that histone acetylation sets the stage for demethylation by gating the accessibility to demethylase we delineated the time course of epigenomic events leading to active demethylation of DNA and transcription of GFP following TSA treatment using ChIP assays with the pertinent epigenomic status antibodies. We show that histone acetylation occurs rapidly and precedes DNA demethylation. The interaction of pol II with the promoter occurs concomitantly with DNA demethylation and is followed by transcription. Our hypothesis is that demethylation is required for pol II interaction with the promoter. Bisulfite mapping of the state of methylation of CMV promoter bound to pol II is underway to test this hypothesis. Interaction of MBD2/demethylase with the CMV promoter occurs after histone acetylation peaks, which is consistent with the hypothesis that histone acetylation state gates the access of MBD2/demethylase with the CMV promoter. Using antisense and siRNA knock-down of MBD2 we show that MBD2/demethylase interaction with the CMV promoter is responsible for GFP demethylation. To determine whether the same mechanism is responsible for active demethylation of endogenous genes we performed an expression micro-array analysis on TSA treated HEK 293 cells to identify endogenous genes that are demethylated by induction of histone acetylation. This study was supported by the National Cancer Institute of Canada.
Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts
Authors: Chih-Cheng Wu, Mu-Yang Hsieh, Szu-Chun Hung, Ko-Lin Kuo, Tung-Hu Tsai, Chao-Lun Lai, Jaw-Wen Chen, Shing-Jong Lin, Po-Hsun Huang, Der-Cherng Tarng
Journal: Journal of the American Society of Nephrology (2015)

Hemodialysis vascular accesses are prone to recurrent stenosis and thrombosis after endovascular interventions.In vitro data suggest that indoxyl sulfate, a protein-bound uremic toxin, may induce vascular dysfunction and thrombosis. However, there is no clinical evidence regarding the role of indoxyl sulfate in hemodialysis vascular access. From January 2010 to June 2013, we prospectively enrolled patients undergoing angioplasty for dialysis access dysfunction. Patients were stratified into tertiles by baseline serum indoxyl sulfate levels. Study participants received clinical follow-up at 6-month intervals until June 2014. Primary end points were restenosis, thrombosis, and failure of vascular access. Median follow-up duration was 32 months. Of the 306 patients enrolled, 262 (86%) had symptomatic restenosis, 153 (50%) had access thrombosis, and 25 (8%) had access failure. In patients with graft access, free indoxyl sulfate tertiles showed a negative association with thrombosis-free patency (thrombosis-free patency rates of 54%, 38%, and 26% for low, middle, and high tertiles, respectively;P=0.001). Patients with graft thrombosis had higher free and total indoxyl sulfate levels. Using multivariate Cox regression analysis, graft thrombosis was independently predicted by absolute levels of free indoxyl sulfate (hazard ratio=1.14;P=0.01) and free indoxyl sulfate tertiles (high versus low, hazard ratio=2.41;P=0.001). Results of this study provide translational evidence that serum indoxyl sulfate is a novel risk factor for dialysis graft thrombosis after endovascular interventions.
Reply: Further Progress in Understanding Fibrosing Mediastinitis
Authors: Tobias Peikert, Blair Westerly, Ulrich Specks
Journal: American Journal of Respiratory and Critical Care Medicine (2015)

pathologic findings, the authors propose that measurement of serum IgG4 may be useful in patients with FM.We write to report a study of serum IgG4 levels in 40 serial patients with FM diagnosed by established clinical and radiographic criteria (1-3, 7).We tested serum IgG subclasses (IgG1, IgG2, IgG3, IgG4) using quantitative nephelometry at ARUP Laboratories (Salt Lake City, UT).IgG subsets were normal in all 40 patients with FM (mean IgG4, 32.3 mg/dl; SD, 24.7 mg/dl; median IgG4, 23.5 mg/dl; interquartile range, 32.3 mg/dl).None had a serum IgG4 above 140 mg/dl, a level recently described to have 96% negative predictive value (8).Our cohort included a broad severity of FM, from unilateral disease with minimal symptoms to bilateral disease with life-threatening complications, and we found no correlation of disease severity with IgG4 levels.More information is needed to understand the discordance between FM tissue and serum IgG4, but it seems possible that for a focal process such as FM, the burden of IgG4-producing plasma cells is not sufficient to increase the level in sera.